Categories | SLE (n = 50) | HCs (n = 27) |
---|---|---|
Females, n (%) | 46 (92) | 23 (85) |
Age, mean (SD), years | 35.5 ± 13.8 | 33.7 ± 10.8 |
SLEDAI score, mean (SD) | 6.3 ± 4.9 | – |
ANA (+, ≥1:100), n (%) | 49 (98.0) | – |
ds-DNA (+, >100 IU/mL), n (%) | 19 (38.0) | – |
Anti-ENA (44 patients) | ||
 Anti-Sm, n (%) | 18 (40.9) | – |
 Anti-Ro52, n (%) | 28 (63.6) | – |
 Anti-nRNP/Sm, n (%) | 28 (63.6) | – |
 Anti-rRNP, n (%) | 21 (47.7) | – |
 Anti-nucleosome, n (%) | 16 (36.4) | – |
 Anti-SSA, n (%) | 37 (84.1) | – |
 Anti-SSB, n (%) | 11 (25.0) | – |
Decreased C3/C4, n (%) | 37 (74.0)/30 (60.0) | – |
Increased IgG, n (%) | 26 (52.0) | – |
Elevated ESR, n (%) | 29 (58.0) | – |
Urine protein (20 patients) | ||
 a1-M > 12.5 mg/L, n (%) | 13 (65.0) |  |
 MALB > 20 mg/L, n (%) | 11 (55.0) |  |
 IgU > 8 mg/L, n (%) | 11 (55.0) |  |
 TRU > 2 mg/L, n (%) | 9 (45.0) |  |
Clinical features | ||
 Fever, n (%) | 8 (16.0) | – |
 Cutaneous manifestations, n (%) | 18 (36.0) | – |
 Oral ulcer, n (%) | 5 (10.0) | – |
 Alopecia, n (%) | 10 (20.0) | – |
 Arthritis, n (%) | 16 (32.0) | – |
 Raynaud’s phenomenon, n (%) | 9 (18.0) | – |
 Effusion, n (%) | 6 (12.0) | – |
 Renal involvement, n (%) | 19 (38.0) | – |
 Hematologic disorder, n (%) | 32 (64.0) | – |
Lymphocytes, mean (SD), %a | 17.2 (9.4)* | 23.7 (6.7) |
CD3+ lymphocytes, mean (SD), %b | 69.9 (12.2)* | 63.4 (7.8) |
CD4+ T subset, mean (SD), %c | 45.9 (12.9)* | 54.4 (9.2) |
CD4+ T subset, mean (SD), /mL | 313.4 (34.2)* | 423.4 (31.3) |
CD8+ T subset, mean (SD), %c | 38.2 (12.8)* | 28.9 (6.5) |
CD8+ T subset, mean (SD), /mL | 419.4 (59.1) | 432.4 (64.9) |
Ratio of CD4+/CD8+T, mean (SD) | 0.98 (0.58)* | 1.29 (0.52) |